Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

MGMT (6-O-methylguanine-DNA methyltransferase)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	temozolomide + lomustine Sensitive: A2 - Guideline temozolomide + lomustine Sensitive : A2	temozolomide + lomustine Sensitive: A2 - Guideline temozolomide + lomustine Sensitive : A2
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
MGMT promoter methylation	Anaplastic Astrocytoma	MGMT promoter methylation	Anaplastic Astrocytoma	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B	temozolomide Sensitive: B - Late Trials temozolomide Sensitive : B
MGMT unmethylation	Glioma	MGMT unmethylation	Glioma	temozolomide + interferon α-2b Sensitive: B - Late Trials temozolomide + interferon α-2b Sensitive : B	temozolomide + interferon α-2b Sensitive: B - Late Trials temozolomide + interferon α-2b Sensitive : B
MGMT promoter methylation	Ewing Sarcoma	MGMT promoter methylation	Ewing Sarcoma	temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria temozolomide + irinotecan Sensitive : C2	temozolomide + irinotecan Sensitive: C2 – Inclusion Criteria temozolomide + irinotecan Sensitive : C2
MGMT underexpression	Glioblastoma	MGMT underexpression	Glioblastoma	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	cilengitide Sensitive: C3 – Early Trials cilengitide Sensitive : C3	cilengitide Sensitive: C3 – Early Trials cilengitide Sensitive : C3
MGMT underexpression	Pituitary Gland Carcinoma	MGMT underexpression	Pituitary Gland Carcinoma	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
MGMT deletion	Neuroendocrine Tumor	MGMT deletion	Neuroendocrine Tumor	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3	cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive: C3 – Early Trials cemiplimab-rwlc + INO-5401 + INO-9012 Sensitive : C3